甲基强的松龙鞘内注射治疗急性期多发性硬化的疗效观察

目的比较甲基强的松龙鞘内注射和冲击疗法在治疗急性期多发性硬化症中的临床疗效。方法将2008年10月～2010年12月住院治疗的56例多发性硬化症患者分为均等的两组,一组为甲基强的松龙鞘内注射,另一组为甲基强的松龙冲击治疗。比较两组的临床疗效、EDSS评分、住院情况以及复发情况。结果鞘内注射MPS组患者临床显效率89.3%显著高于MPS组82.1%(P<0.05);鞘内注射MPS组EDSS(2.4±1.1)分,显著低于MPS冲击组(3.5±1.6)分,(P<0.05);鞘内注射MPS组患者平均住院时间(17.4±3.8)d短于MPS冲击组(32.5±4.2)(dP<0.05),住院费用(5341.2±1437.3)元也低于MPS冲击组(9766.8±1728.7)元(P<0.05);鞘内注射MPS组患者复发率17.9%相对较低,且患者复发的平均间隔时间(11.5±1.4)个月也明显短于MPS冲击组(5.1±1.2)个月(P<0.05)。结论鞘内注射甲基强的松龙治疗急性期多发性硬化症疗效更快,患者住院时间短,神经功能恢复快,且复发率低。

Objective To compare the clinical efficacy for methyl prednisolone intrathecal injection and shock therapy in the treatment of acute multiple Sclerosis. Methods 56 patients with multiple sclerosis patients hospitalized from October 2008 to 2010 were divided into the equal two groups. One group was taken for intrathecal injection of methylprednisolone, and the other group was taken with methylprednisolone pulse therapy. The clinical efficacy, EDSS scores, hospitalizations, and recurrence rate for the two groups were compared. Results The clinically significant efficiency for intrathecal injection of MPS group 89.3%was significantly higher than the MPS group 82.1% （P〈0.05）. The EDSS for intrathecal injection MPS Group （2.4＋1.1） scores was significantly lower than the MPS shocking group （3.5±1.6） scores （P〈0.05）. The average length of stay for intrathecal injection of MPS group （17.4±3.8） days was shorter than the MPS shock group （32.5±4.2） days （P〈0.05）, and hospitalization costs （5341.2±1437.3） Yuan was lower than the MPS shocking group （9766.8±1728.7） Yuan （P〈0.05）. The relapse rate for intrathecal injection of MPS patients 17.9% was relatively low, and the average interval in patients （11.5±1.4） months was significantly shorter than the MPS shock group （5.1±1.2） months （P〈0.05）. Conclusion The efficacy for intrathecal injection of methylprednisolone in the treatment of multiple sclerosis during the acute phase is fast, the period of hospitalization is short, and it is with a faster recovery of neurological fimction and low recurrence rate.